We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer has several programs for possible genetic cures it is shepherding through its pipeline, including one with partner Sangamo Therapeutics for treating hemophilia A and another for Duchenne muscular dystrophy.